Literature DB >> 25787981

Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Timothy E Andrews1, Dan Wang, Daniel A Harki.   

Abstract

The recognition that the persistence of cancer stem cells (CSCs) in patients following chemotherapy can result in disease relapse underscores the necessity to develop therapeutics against those cells. CSCs display a unique repertoire of cell surface macromolecules, which have proven essential for their characterization and isolation. Additionally, CSC-specific cell surface macromolecules or markers provide targets for the development of specific agents to destroy them. In this review, we compiled those cell surface molecules that have been validated as CSC markers for many common blood and solid tumors. We describe the unique chemical and structural features of the most common cell surface markers, as well as recent efforts to deliver chemotherapeutic agents into CSCs by targeting those macromolecules.

Entities:  

Year:  2013        PMID: 25787981     DOI: 10.1007/s13346-012-0075-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  226 in total

Review 1.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

2.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

Review 3.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

4.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

6.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

7.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

Review 8.  Cancer stem cells: at the headwaters of tumor development.

Authors:  Ryan J Ward; Peter B Dirks
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

9.  Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells.

Authors:  Y M Yang; J W Chang
Journal:  Cancer Invest       Date:  2008-08       Impact factor: 2.176

10.  Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.

Authors:  Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Hagop M Kantarjian
Journal:  Rev Clin Exp Hematol       Date:  2002-06
View more
  8 in total

1.  Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.

Authors:  Alireza Mirzaei; Gholamreza Tavoosidana; Mohammad Hossein Modarressi; Afshin Abdi Rad; Mohammad Sadegh Fazeli; Reza Shirkoohi; Masoumeh Tavakoli-Yaraki; Zahra Madjd
Journal:  Tumour Biol       Date:  2015-01-29

2.  Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.

Authors:  Aaron M Kempema; John C Widen; Joseph K Hexum; Timothy E Andrews; Dan Wang; Susan K Rathe; Frederick A Meece; Klara E Noble; Zohar Sachs; David A Largaespada; Daniel A Harki
Journal:  Bioorg Med Chem       Date:  2015-05-30       Impact factor: 3.641

Review 3.  Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.

Authors:  Peyman Ranji; Tayyebali Salmani Kesejini; Sara Saeedikhoo; Ali Mohammad Alizadeh
Journal:  Tumour Biol       Date:  2016-08-26

4.  Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation.

Authors:  Efraín A Cermeño; Andrés J García
Journal:  Curr Stem Cell Rep       Date:  2016-02-09

Review 5.  Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.

Authors:  Quinty Hansen; Costa Bachas; Linda Smit; Jacqueline Cloos
Journal:  Cancer Drug Resist       Date:  2022-05-05

Review 6.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

7.  Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma.

Authors:  Wuniqiemu Tulake; Reziwanguli Yuemaier; Lei Sheng; Mingfang Ru; Dilare Lidifu; Abulizi Abudula
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

8.  Effect of Cinnamic acid and FOLFOX in diminishing side population and downregulating cancer stem cell markers in colon cancer cell line HT-29.

Authors:  Sara Soltanian; Helia Riahirad; Athareh Pabarja; Elham Jafari; Behjat Kalantari Khandani
Journal:  Daru       Date:  2018-09-12       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.